CiQUS - Center for Research in Biological Chemistry and Molecular Materials

CiQUS (USC) aimed at generating groundbreaking science at the intersection of Chemistry, Biology & Materials Science.
We comprise 18 research groups and over 200 people, which were awarded 12 ERC projects (4 ERC-PoC). CiQUS reached almost 10 MEUR/year (2021-2023) in competitive funds, and an Impact Factor of 9.5 (JCR, 2022).

Key Words - Biomed: • Drug & nuclei acid delivery: non-immunogenic peptide carriers, stimuli-responsibe hybrid nanocomposites, MOFs, dendrimers...); • New catalytic nanomaterials in living settings; • Fluorescent tools in drug discovery; • Molecular dynamics; • Bio-supramolecular chemistry & nanotechnology;
Check our Tecnology Offers.

EU Projects - Biomed (check all our Research projects):

• EIC-Transition “TraffikGene-Tx”: Targeted Peptide Carriers for RNA Delivery.
• EIC-Pathfinder “CAR T-REX”: CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment.
• CaixaResearch Consolidate 2021: Eliminating cancer stem cells: inhibition of mitochondrial respiration.
• AECC 2021: Anticancer drugs: selective cleavage of DNA three-way junctions by CU(II) peptide.
• AECC 2020: Novel vaccine approach for cancer immunotherapy based on protein microspheres.
• Adjuvant-free subunit vaccines for COVID-19 (Funds: ISCII – Spain & European Vaccine Initiative).
• FET-OPEN “SWIMMOT”: Switchable magneto-plasmonic contrast agents and molecular imaging.
• H2020-ICT “REAP”: Revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacustic tomography.
• H2020-SC1 "ENDOSCAPE": Clinically applicable non-viral gene delivery technology”.
• ERC-PoC “antiCSC”: Targeting the cancer stem cell metabolism with reactive metal complexes.